Viridian Therapeutics, Inc./DE Convertible Notes Payable, Noncurrent
Viridian Therapeutics, Inc./DE (VRDN) had Convertible Notes Payable, Noncurrent of $242.16 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt, Excluding Current Maturities
us-gaap:ConvertibleLongTermNotesPayable · last filed 2026-08-06
- 2026-06-30: Convertible Notes Payable, Noncurrent $242.16M.
- 2025-12-31: Convertible Notes Payable, Noncurrent $0.00.
| Period end | Convertible Notes Payable, Noncurrent |
|---|---|
| 2026-06-30 | $242.16M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |